Rahul Lall

EECS Department, University of California, Berkeley

Technical Report No. UCB/EECS-2024-41

May 1, 2024

http://www2.eecs.berkeley.edu/Pubs/TechRpts/2024/EECS-2024-41.pdf

Cancer radiopharmaceutical therapies (RPTs) have demonstrated great promise in the treatment of neuroendocrine and prostate cancer, giving hope to late-stage metastatic cancer patients with currently very few treatment options. These therapies have sparked a large amount of interest in pre-clinical research due to their ability to target metastatic disease, with many research efforts focused towards developing and evaluating targeted RPTs for different cancer types in in vivo models. Here we describe a method for monitoring real-time in vivo binding kinetics for the pre-clinical evaluation of cancer RPTs. Recognizing the significant heterogeneity in biodistribution of RPTs among even genetically identical animal models, this approach offers long-term monitoring of the same in vivo organism without euthanasia in contrast to ex vivo tissue dosimetry, while providing high temporal resolution with a low-cost, easily assembled platform, that is not present in small-animal SPECT/CTs. The method utilizes the developed optical fiber-based γ-photon biosensor, characterized to have a wide linear dynamic range with Lutetium-177 (Lu-177) activity (0.5-500µCi/mL), a common radioisotope used in cancer RPT. The probe’s ability to track in vivo uptake relative to SPECT/CT and ex vivo dosimetry techniques was verified by administering Lu-177-PSMA-617 to mouse models bearing human prostate cancer tumors (PC3-pip, PC3-flu). With this method for monitoring RPT uptake, it is possible to evaluate changes in tissue uptake at temporal resolutions less than 1 minute to determine RPT biodistribution in pre-clinical models and better understand dose relationships with tumor ablation, toxicity, and recurrence when attempting to move therapies towards clinical trial validation.

Advisors: Ali Niknejad and Mekhail Anwar

---

BibTeX citation:

@mastersthesis{Lall:EECS-2024-41,
    Author= {Lall, Rahul},
    Title= {Optical Fiber-based γ-Photon Biosensor for Real-Time Pre-clinical Evaluation of Cancer-Targeting Radiopharmaceuticals},
    School= {EECS Department, University of California, Berkeley},
    Year= {2024},
    Month= {May},
    Url= {http://www2.eecs.berkeley.edu/Pubs/TechRpts/2024/EECS-2024-41.html},
    Number= {UCB/EECS-2024-41},
    Abstract= {Cancer radiopharmaceutical therapies (RPTs) have demonstrated great promise in the treatment of neuroendocrine and prostate cancer, giving hope to late-stage metastatic cancer patients with currently very few treatment options. These therapies have sparked a large amount of interest in pre-clinical research due to their ability to target metastatic disease, with many research efforts focused towards developing and evaluating targeted RPTs for different cancer types in in vivo models. Here we describe a method for monitoring real-time in vivo binding kinetics for the pre-clinical evaluation of cancer RPTs. Recognizing the significant heterogeneity in biodistribution of RPTs among even genetically identical animal models, this approach offers long-term monitoring of the same in vivo organism without euthanasia in contrast to ex vivo tissue dosimetry, while providing high temporal resolution with a low-cost, easily assembled platform, that is not present in small-animal SPECT/CTs. The method utilizes the developed optical fiber-based γ-photon biosensor, characterized to have a wide linear dynamic range with Lutetium-177 (Lu-177) activity (0.5-500µCi/mL), a common radioisotope used in cancer RPT. The probe’s ability to track in vivo uptake relative to SPECT/CT and ex vivo dosimetry techniques was verified by administering Lu-177-PSMA-617 to mouse models bearing human prostate cancer tumors (PC3-pip, PC3-flu). With this method for monitoring RPT uptake, it is possible to evaluate changes in tissue uptake at temporal resolutions less than 1 minute to determine RPT biodistribution in pre-clinical models and better understand dose relationships with tumor ablation, toxicity, and recurrence when attempting to move therapies towards clinical trial validation.},
}

EndNote citation:

%0 Thesis
%A Lall, Rahul 
%T Optical Fiber-based γ-Photon Biosensor for Real-Time Pre-clinical Evaluation of Cancer-Targeting Radiopharmaceuticals
%I EECS Department, University of California, Berkeley
%D 2024
%8 May 1
%@ UCB/EECS-2024-41
%U http://www2.eecs.berkeley.edu/Pubs/TechRpts/2024/EECS-2024-41.html
%F Lall:EECS-2024-41